Literature DB >> 21164474

Drug discovery: How melanomas bypass new therapy.

David Solit, Charles L Sawyers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21164474     DOI： 10.1038/468902a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  13 in total

1.  Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

Authors:  Steven Whittaker; Ruth Kirk; Robert Hayward; Alfonso Zambon; Amaya Viros; Neus Cantarino; Annette Affolter; Arnaud Nourry; Dan Niculescu-Duvaz; Caroline Springer; Richard Marais
Journal:  Sci Transl Med       Date:  2010-06-09       Impact factor: 17.956

2.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

3.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Authors:  Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek
Journal:  Nature       Date:  2010-02-03       Impact factor: 49.962

4.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

5.  Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

Authors:  Clara Montagut; Sreenath V Sharma; Toshi Shioda; Ultan McDermott; Matthew Ulman; Lindsey E Ulkus; Dora Dias-Santagata; Hannah Stubbs; Diana Y Lee; Anurag Singh; Lisa Drew; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

6.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

7.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

8.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors:  Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

9.  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors:  Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

10.  COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors:  Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962
View more
  22 in total

Review 1.  The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.

Authors:  Michael P Brown; Eva Bezak; Barry J Allen
Journal:  Melanoma Manag       Date:  2015-11-24

Review 2.  Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.

Authors:  Rolando Pérez-Lorenzo; Bin Zheng
Journal:  Biosci Rep       Date:  2012-02       Impact factor: 3.840

3.  Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.

Authors:  Raghavendra Gowda; Gregory Kardos; Arati Sharma; Sanjay Singh; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2016-12-21       Impact factor: 6.261

4.  Melanoma: Molecular Pathogenesis and Therapeutic Management.

Authors:  Yuxin Liu; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2014

5.  Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2011-12       Impact factor: 4.677

6.  Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Authors:  Arati Sharma; SubbaRao V Madhunapantula; Raghavendra Gowda; Arthur Berg; Rogerio I Neves; Gavin P Robertson
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

7.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

Authors:  Sergey I Nikolaev; Donata Rimoldi; Christian Iseli; Armand Valsesia; Daniel Robyr; Corinne Gehrig; Keith Harshman; Michel Guipponi; Olesya Bukach; Vincent Zoete; Olivier Michielin; Katja Muehlethaler; Daniel Speiser; Jacques S Beckmann; Ioannis Xenarios; Thanos D Halazonetis; C Victor Jongeneel; Brian J Stevenson; Stylianos E Antonarakis
Journal:  Nat Genet       Date:  2011-12-25       Impact factor: 38.330

8.  Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.

Authors:  Michael Röring; Ricarda Herr; Gina J Fiala; Katharina Heilmann; Sandra Braun; Anja E Eisenhardt; Sebastian Halbach; David Capper; Andreas von Deimling; Wolfgang W Schamel; Darren N Saunders; Tilman Brummer
Journal:  EMBO J       Date:  2012-04-17       Impact factor: 11.598

Review 9.  The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Authors:  Moriah H Nissan; David B Solit
Journal:  Curr Oncol Rep       Date:  2011-12       Impact factor: 5.075

Review 10.  A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.

Authors:  Joost C M Uitdehaag; Folkert Verkaar; Husam Alwan; Jos de Man; Rogier C Buijsman; Guido J R Zaman
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.